Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $354.32 million. The enterprise value is $183.69 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 55.71 million shares outstanding. The number of shares has increased by 6.15% in one year.
| Current Share Class | 43.25M |
| Shares Outstanding | 55.71M |
| Shares Change (YoY) | +6.15% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 16.85% |
| Owned by Institutions (%) | 50.01% |
| Float | 37.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| Forward PS | 1.59 |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.79, with a Debt / Equity ratio of 0.56.
| Current Ratio | 5.79 |
| Quick Ratio | 5.59 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5,790.88 |
Financial Efficiency
Return on equity (ROE) is -63.51% and return on invested capital (ROIC) is -23.21%.
| Return on Equity (ROE) | -63.51% |
| Return on Assets (ROA) | -19.19% |
| Return on Capital (ROIC) | -23.21% |
| Revenue Per Employee | $178,942 |
| Profits Per Employee | -$534,638 |
| Employee Count | 1,218 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -352,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.54% in the last 52 weeks. The beta is 1.10, so DNA's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -89.54% |
| 50-Day Moving Average | 7.82 |
| 200-Day Moving Average | 23.19 |
| Relative Strength Index (RSI) | 34.48 |
| Average Volume (20 Days) | 1,223,754 |
Short Selling Information
The latest short interest is 7.33 million, so 13.15% of the outstanding shares have been sold short.
| Short Interest | 7.33M |
| Short Previous Month | 8.19M |
| Short % of Shares Out | 13.15% |
| Short % of Float | 19.54% |
| Short Ratio (days to cover) | 8.73 |
Income Statement
In the last 12 months, DNA had revenue of $217.95 million and -$651.19 million in losses. Loss per share was -$12.86.
| Revenue | 217.95M |
| Gross Profit | 176.41M |
| Operating Income | -538.55M |
| Pretax Income | -897.68M |
| Net Income | -651.19M |
| EBITDA | -477.30M |
| EBIT | -538.55M |
| Loss Per Share | -$12.86 |
Full Income StatementBalance Sheet
The company has $616.21 million in cash and $445.59 million in debt, giving a net cash position of $170.62 million or $3.06 per share.
| Cash & Cash Equivalents | 616.21M |
| Total Debt | 445.59M |
| Net Cash | 170.62M |
| Net Cash Per Share | $3.06 |
| Equity (Book Value) | 797.94M |
| Book Value Per Share | 15.03 |
| Working Capital | 548.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$334.98 million and capital expenditures -$52.28 million, giving a free cash flow of -$387.26 million.
| Operating Cash Flow | -334.98M |
| Capital Expenditures | -52.28M |
| Free Cash Flow | -387.26M |
| FCF Per Share | -$6.95 |
Full Cash Flow StatementMargins
Gross margin is 80.94%, with operating and profit margins of -247.10% and -298.78%.
| Gross Margin | 80.94% |
| Operating Margin | -247.10% |
| Pretax Margin | -298.94% |
| Profit Margin | -298.78% |
| EBITDA Margin | -218.99% |
| EBIT Margin | -247.10% |
| FCF Margin | -187.11% |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.15% |
| Shareholder Yield | -6.15% |
| Earnings Yield | -183.79% |
| FCF Yield | -109.30% |
Dividend DetailsAnalyst Forecast
The average price target for DNA is $37.80, which is 494.34% higher than the current price. The consensus rating is "Hold".
| Price Target | $37.80 |
| Price Target Difference | 494.34% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 24.90% |
| EPS Growth Forecast (5Y) | -66.48% |
Stock ForecastsStock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
DNA has an Altman Z-Score of -4.32 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.32 |
| Piotroski F-Score | 2 |